FY2024 EPS Estimates for Genmab A/S Boosted by William Blair

Genmab A/S (NASDAQ:GMAB) – Equities researchers at William Blair boosted their FY2024 earnings estimates for shares of Genmab A/S in a research report issued on Wednesday, November 6th. William Blair analyst M. Phipps now expects that the company will earn $1.24 per share for the year, up from their prior estimate of $1.22. The consensus estimate for Genmab A/S’s current full-year earnings is $1.29 per share. William Blair also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.34 EPS, FY2025 earnings at $1.60 EPS, FY2026 earnings at $2.52 EPS and FY2027 earnings at $3.56 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%.

A number of other analysts have also issued reports on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

Genmab A/S stock opened at $23.08 on Friday. The firm’s fifty day moving average price is $24.39 and its 200 day moving average price is $26.41. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99. Genmab A/S has a 12-month low of $21.90 and a 12-month high of $32.89.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its holdings in shares of Genmab A/S by 360.5% during the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after acquiring an additional 23,094 shares during the period. Capital International Investors grew its holdings in Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 26.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares during the period. Choreo LLC bought a new stake in Genmab A/S during the 2nd quarter valued at $776,000. Finally, Renaissance Technologies LLC grew its stake in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.